Tobey J Macdonald

List of Publications by Year
in descending order

127 papers	6,161 citations	76326 40 h-index	76900 74 g-index
130 all docs	130 docs citations	130 times ranked	9335 citing authors

#	Article	IF	Citations
1	Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nature Genetics, 2001, 29, 143-152.	21.4	421
2	Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature, 2012, 482, 529-533.	27.8	376
3	Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. Journal of Clinical Investigation, 2011, 121, 148-160.	8.2	297
4	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	10.7	268
5	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	27.8	266
6	Medulloblastoma in childhood: new biological advances. Lancet Neurology, The, 2007, 6, 1073-1085.	10.2	239
7	Microengineered human bloodâ€“brain barrier platform for understanding nanoparticle transport mechanisms. Nature Communications, 2020, 11, 175.	12.8	236
8	Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an Î±v Integrin Antagonist. Neurosurgery, 2001, 48, 151-157.	1.1	211
9	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	9.4	157
10	Preclinical Evaluation of Radiation and Perifosine in a Genetically and Histologically Accurate Model of Brainstem Glioma. Cancer Research, 2010, 70, 2548-2557.	0.9	149
11	Medulloblastoma: Present Concepts of Stratification into Risk Groups. Pediatric Neurosurgery, 2003, 39, 60-67.	0.7	145
12	Phase I Clinical Trial of Cilengitide in Children With Refractory Brain Tumors: Pediatric Brain Tumor Consortium Study PBTC-012. Journal of Clinical Oncology, 2008, 26, 919-924.	1.6	143
13	The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. , 2014, 2, 21.		132
14	Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro-Oncology, 2017, 19, 1542-1552.	1.2	130
15	Guiding intracortical brain tumour cells to an extracortical cytotoxic hydrogel using aligned polymeric nanofibres. Nature Materials, 2014, 13, 308-316.	27.5	128
16	Treatment of high-grade glioma in children and adolescents. Neuro-Oncology, 2011, 13, 1049-1058.	1.2	127
17	Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma. Neuro-Oncology, 2016, 18, 881-887.	1.2	122
18	Secretome Signature of Invasive Glioblastoma Multiforme. Journal of Proteome Research, 2011, 10, 3149-3159.	3.7	115

#	Article	IF	Citations
19	Clinical Outcomes Among Children With Standard-Risk Medulloblastoma Treated With Proton and Photon Radiation Therapy: A Comparison of Disease Control and Overall Survival. International Journal of Radiation Oncology Biology Physics, 2016, 94, 133-138.	0.8	105
20	Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma. Nature Communications, 2019, 10, 2410.	12.8	99
21	Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes. Acta Neuropathologica, 2014, 127, 881-895.	7.7	91
22	Phase I Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory, or Progressive Primary CNS Tumors: Pediatric Brain Tumor Consortium Study PBTC-018. Journal of Clinical Oncology, 2011, 29, 324-329.	1.6	83
23	Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro-Oncology, 2018, 20, 1547-1555.	1.2	82
24	Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathologica, 2015, 129, 449-457.	7.7	80
25	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncology, The, 2020, 21, e317-e329.	10.7	69
26	Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Child's Nervous System, 2013, 29, 589-596.	1.1	66
27	Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma. Cancer, 2005, 104, 2862-2871.	4.1	58
28	Three-Dimensional Mass Spectrometry Imaging Identifies Lipid Markers of Medulloblastoma Metastasis. Scientific Reports, 2019, 9, 2205.	3.3	57
29	Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor. Molecular Cancer Therapeutics, 2009, 8, 1137-1147.	4.1	55
30	Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study. Proteomics, 2011, 11, 935-943.	2.2	54
31	The rationale for targeted therapies in medulloblastoma. Neuro-Oncology, 2014, 16, 9-20.	1.2	54
32	Aggressive Infantile Embryonal Tumors. Journal of Child Neurology, 2008, 23, 1195-1204.	1.4	52
33	A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric lowâ€grade glioma (LGG). Pediatric Blood and Cancer, 2013, 60, 71-76.	1.5	52
34	BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation. Cancer Cell, 2018, 33, 1004-1016.e5.	16.8	52
35	A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma. Clinical Cancer Research, 2015, 21, 585-593.	7.0	50
36	REST Is a Novel Prognostic Factor and Therapeutic Target for Medulloblastoma. Molecular Cancer Therapeutics, 2012, 11, 1713-1723.	4.1	47

#	Article	IF	Citations
37	Single-cell analysis reveals effective siRNA delivery in brain tumors with microbubble-enhanced ultrasound and cationic nanoparticles. Science Advances, 2021, 7, .	10.3	47
38	PEG-b-AGE polymer coated magnetic nanoparticle probes with facile functionalization and anti-fouling properties for reducing non-specific uptake and improving biomarker targeting. Journal of Materials Chemistry B, 2015, 3, 3591-3603.	5.8	45
39	Rapid discrimination of pediatric brain tumors by mass spectrometry imaging. Journal of Neuro-Oncology, 2018, 140, 269-279.	2.9	45
40	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro-Oncology, 2020, 22, 773-784.	1.2	44
41	Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells. Journal of Neuro-Oncology, 2011, 101, 215-226.	2.9	43
42	Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma. Brain, 2021, 144, 53-69.	7.6	43
43	Successful Retreatment of a Child with a Refractory Brainstem Ganglioglioma with Vemurafenib. Pediatric Blood and Cancer, 2016, 63, 541-543.	1.5	42
44	ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration. Clinical and Experimental Metastasis, 2010, 27, 481-491.	3.3	41
45	Pediatric Phase II Trials of Poly-ICLC in the Management of Newly Diagnosed and Recurrent Brain Tumors. Journal of Pediatric Hematology/Oncology, 2014, 36, 451-457.	0.6	41
46	Heterozygosity for Pten Promotes Tumorigenesis in a Mouse Model of Medulloblastoma. PLoS ONE, 2010, 5, e10849.	2.5	40
47	Medulloblastoma and primitive neuroectodermal tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 105, 529-548.	1.8	38
48	Improving sensitivity and specificity of capturing and detecting targeted cancer cells with anti-biofouling polymer coated magnetic iron oxide nanoparticles. Colloids and Surfaces B: Biointerfaces, 2017, 150, 261-270.	5.0	37
49	Detection of Brain Tumor Invasion and Micrometastasis in Vivo by Expression of Enhanced Green Fluorescent Protein. Neurosurgery, 1998, 43, 1437-1442.	1.1	36
50	Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children's Oncology Group. Neuro-Oncology, 2013, 15, 1438-1444.	1.2	36
51	Clinical responses of patients with diffuse leptomeningeal glioneuronal tumors to chemotherapy. Child's Nervous System, 2018, 34, 329-334.	1.1	36
52	Engineered biomimetic nanoparticle for dual targeting of the cancer stem-like cell population in sonic hedgehog medulloblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24205-24212.	7.1	32
53	Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. , 2020, 8, e001066.		30
54	The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma. Oncotarget, 2015, 6, 12141-12155.	1.8	30

#	Article	IF	Citations
55	Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration. Molecular Cancer, 2013, 12, 18.	19.2	29
56	Diffuse intrinsic pontine glioma (DIPG): Time to biopsy again?. Pediatric Blood and Cancer, 2012, 58, 487-488.	1.5	28
57	Progression-Associated Genes in Astrocytoma Identified by Novel Microarray Gene Expression Data Reanalysis. Methods in Molecular Biology, 2007, 377, 203-221.	0.9	27
58	Detection of Brain Tumor Invasion and Micrometastasis in Vivo by Expression of Enhanced Green Fluorescent Protein. Neurosurgery, 1998, 43, 1437-1442.	1.1	27
59	Phase I study of tandem highâ€dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: A pediatric blood and marrow transplant consortium study. Pediatric Blood and Cancer, 2011, 57, 506-513.	1.5	25
60	Transient enlargement of craniopharyngioma after radiation therapy: pattern of magnetic resonance imaging response following radiation. Journal of Neuro-Oncology, 2012, 109, 349-355.	2.9	25
61	Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization. Oncotarget, 2015, 6, 8929-8946.	1.8	25
62	The Use of Gene Expression Analysis to Gain Insights into Signaling Mechanisms of Metastatic Medulloblastoma. Pediatric Neurosurgery, 2003, 39, 68-74.	0.7	23
63	A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. Pediatric Blood and Cancer, 2020, 67, e28134.	1.5	22
64	Tumour immune landscape of paediatric high-grade gliomas. Brain, 2021, 144, 2594-2609.	7.6	21
65	White matter network topology relates to cognitive flexibility and cumulative neurological risk in adult survivors of pediatric brain tumors. NeuroImage: Clinical, 2018, 20, 485-497.	2.7	20
66	Transcriptional repressor REST drives lineage stageâ€“specific chromatin compaction at Ptch1 and increases AKT activation in a mouse model of medulloblastoma. Science Signaling, 2019, 12, .	3.6	19
67	A MCP1 fusokine with CCR2-specific tumoricidal activity. Molecular Cancer, 2011, 10, 121.	19.2	18
68	Identification of transcriptional regulatory networks specific to pilocytic astrocytoma. BMC Medical Genomics, 2011, 4, 57.	1.5	18
69	Prolonged Survival After Treatment of Diffuse Intrinsic Pontine Glioma with Radiation, Temozolamide, and Bevacizumab. Journal of Pediatric Hematology/Oncology, 2013, 35, e42-e46.	0.6	18
70	VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biology and Therapy, 2011, 12, 818-826.	3.4	17
71	A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and highâ€grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. Pediatric Blood and Cancer, 2017, 64, e26621.	1.5	17
72	Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283. Cancer Letters, 2014, 354, 68-76.	7.2	16

#	Article	IF	Citations
73	Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. Neuro-Oncology, 2022, 24, 1964-1975.	1.2	15
74	A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncology, 2022, 11, CNS87.	3.0	15
75	Intellectual functioning among caseâ€matched cohorts of children treated with proton or photon radiation for standardâ€risk medulloblastoma. Cancer, 2021, 127, 3840-3846.	4.1	14
76	EphrinB1 expression is dysregulated and promotes oncogenic signaling in medulloblastoma. Journal of Neuro-Oncology, 2015, 121, 109-118.	2.9	12
77	Central Nervous System Tumors. Hematology/Oncology Clinics of North America, 2010, 24, 87-108.	2.2	11
78	Neurofibromatosis-2 and spinal cord ependymomas: Report of two cases and review of the literature. Child's Nervous System, 2011, 27, 757-764.	1.1	11
79	Characterization of signaling function and expression of HLA class I molecules in medulloblastoma. Journal of Neuro-Oncology, 2011, 103, 197-206.	2.9	10
80	Response of Subependymal Giant Cell Astrocytoma With Spinal Cord Metastasis to Everolimus. Journal of Pediatric Hematology/Oncology, 2014, 36, e448-e451.	0.6	9
81	Host Genome Variation is Associated with Neurocognitive Outcome in Survivors of Pediatric Medulloblastoma. Translational Oncology, 2019, 12, 908-916.	3.7	9
82	GSTP1 polymorphisms sex-specific association with verbal intelligence in survivors of pediatric medulloblastoma tumors. Child Neuropsychology, 2020, 26, 739-753.	1.3	9
83	Hedgehog Pathway in Pediatric Cancers: They're Not Just for Brain Tumors Anymore. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 605-609.	3.8	8
84	Liposome-Imipramine Blue Inhibits Sonic Hedgehog Medulloblastoma In Vivo. Cancers, 2021, 13, 1220.	3.7	8
85	STAT3 is required for Smoâ€dependent signaling and mediates Smoâ€targeted treatment resistance and tumorigenesis in Shh medulloblastoma. Molecular Oncology, 2022, 16, 1009-1025.	4.6	7
86	PDCT-06. RADIO-IMMUNOTHERAPY USING THE IDO-INHIBITOR INDOXIMOD IN COMBINATION WITH RE-IRRADIATION FOR CHILDREN WITH PROGRESSIVE BRAIN TUMORS IN THE PHASE 1 SETTING: AN UPDATED REPORT OF SAFETY AND TOLERABILITY (NCT02502708). Neuro-Oncology, 2017, 19, vi185-vi185.	1.2	6
87	ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma.. Journal of Clinical Oncology, 2019, 37, 10046-10046.	1.6	6
88	Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. Neuro-Oncology, 2023, 25, 199-210.	1.2	6
89	Lipidome signatures of metastasis in a transgenic mouse model of sonic hedgehog medulloblastoma. Analytical and Bioanalytical Chemistry, 2020, 412, 7017-7027.	3.7	5
90	Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.. Journal of Clinical Oncology, 2020, 38, 2563-2563.	1.6	5

#	Article	IF	Citations
91	IMMU-04. FIRST-IN-CHILDREN PHASE 1B STUDY USING THE IDO PATHWAY INHIBITOR INDOXIMOD IN COMBINATION WITH RADIATION AND CHEMOTHERAPY FOR CHILDREN WITH NEWLY DIAGNOSED DIPG (NCT02502708, NLG2105). Neuro-Oncology, 2021, 23, i27-i27.	1.2	4
92	LGG-52. BINIMETINIB IN CHILDREN WITH PROGRESSIVE OR RECURRENT LOW-GRADE GLIOMA NOT ASSOCIATED WITH NEUROFIBROMATOSIS TYPE 1: INITIAL RESULTS FROM A MULTI-INSTITUTIONAL PHASE II STUDY. Neuro-Oncology, 2020, 22, iii376-iii376.	1.2	4
93	Abstract CT004: Front-line therapy of DIPG using the IDO pathway inhibitor indoximod in combination with radiation and chemotherapy. , 2018, , .		4
94	LGG-58. A PHASE II TRIAL OF POLY-ICLC IN THE MANAGEMENT OF RECURRENT OR PROGRESSIVE PEDIATRIC LOW GRADE GLIOMAS (NCT01188096): PRELIMINARY ANALYSIS. Neuro-Oncology, 2018, 20, i116-i117.	1.2	2
95	PDCT-24. AÂPHASE IÂDOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS-RAF PATHWAY-ACTIVATED TUMORS: INITIAL REPORT. Neuro-Oncology, 2017, 19, vi189-vi189.	1.2	1
96	PDCT-20. FEASIBILITY AND SAFETY OF SURGICAL BIOPSY FOR PATIENTS WITH DIPG: PRELIMINARY RESULTS FROM DIPG-BATS. Neuro-Oncology, 2017, 19, vi188-vi188.	1.2	1
97	PDCT-03. A PHASE II TRIAL OF POLY-ICLC IN THE MANAGEMENT OF RECURRENT OR PROGRESSIVE PEDIATRIC LOW GRADE GLIOMAS. RESULTS FOR THE NEUROFIBROMATOSIS 1 GROUP. (NCT01188096). Neuro-Oncology, 2018, 20, vi201-vi201.	1.2	1
98	EAPH-10. SUCCESSFUL TREATMENT OF A SECONDARY PEDIATRIC HIGH GRADE GLIOMA WITH A NOVEL BEND4-NTRK2 FUSION WITH ENTRECTINIB, A TRK INHIBITOR. Neuro-Oncology, 2018, 20, i67-i67.	1.2	1
99	Integrated analysis of pediatric low-grade glioma: clinical implications and the path forward. Neuro-Oncology, 2020, 22, 1413-1414.	1.2	1
100	Abstract 3196: STAT3 inhibitor WP1066 as a novel therapeutic for medulloblastoma. , 2016, , .		1
101	Abstract C002: Phase 1 study of abemaciclib in children with recurrent and refractory solid tumors including malignant brain tumors. , 2019, , .		1
102	EPCT-02. PBTC-051: FIRST IN PEDIATRICS PHASE 1 STUDY OF CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M IN PEDIATRIC SUBJECTS WITH RECURRENT/REFRACTORY BRAIN TUMORS. Neuro-Oncology, 2020, 22, iii304-iii304.	1.2	1
103	CTNI-15. CLINICAL EFFICACY OF ONC201 IN NEWLY DIAGNOSED DIPG AND IN PREVIOUSLY IRRADIATED PEDIATRIC H3 K27M-MUTANT GLIOMAS. Neuro-Oncology, 2020, 22, ii45-ii45.	1.2	1
104	HGG-34. Upfront Molecular Targeted Therapy for the Treatment of BRAF-mutant Pediatric High-Grade Glioma. Neuro-Oncology, 2022, 24, i68-i68.	1.2	1
105	LGG-64. A Phase II Study of Pegylated Interferon in Children with Recurrent or Refractory and Radiographically or Clinically Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas (NCT02343224). Neuro-Oncology, 2022, 24, i103-i103.	1.2	1
106	Window-of-opportunity study of ONC201 in pediatric patients with diffuse intrinsic pontine glioma (DIPG) and thalamic glioma.. Journal of Clinical Oncology, 2022, 40, TPS2082-TPS2082.	1.6	1
107	New Directions in Pediatric Neuro-Oncology Practice: Impact of the Children's Cancer Group Study 9933, a Phase II Study of High-Dose Chemotherapy Before Radiation in Children with Newly Diagnosed High-Grade Astrocytoma. Progress in Neurotherapeutics and Neuropsychopharmacology, 2007, 2, 109-122.	0.0	0
108	HG-41OUTCOMES FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA ENROLLED ON PHASE II CLINICAL TRIALS: AN ANALYSIS OF CONTEMPORARY CHILDREN'S ONCOLOGY GROUP (COG) AND PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) TRIALS. Neuro-Oncology, 2016, 18, iii56.4-iii56.	1.2	0

#	Article	IF	Citations
109	MB-107REST ELEVATION UNRESTRAINS SHH SIGNALING IN MEDULLOBLASTOMA. Neuro-Oncology, 2016, 18, iii121.3-iii121.	1.2	0
110	PDTB-09. ORGANOTYPIC TUMOR SLICE CULTURE FOR EVALUATING TREATMENT OF MEDULLOBLASTOMA. Neuro-Oncology, 2016, 18, vi151-vi151.	1.2	0
111	PDTB-28. TARGETING MEDULLOBLASTOMA WITH BENZODIAZAPINES DELIVERED USING TUNABLE BIODEGRADABLE HYDROGELS. Neuro-Oncology, 2016, 18, vi156-vi156.	1.2	0
112	CSIG-26. MET FUSION, AMPLIFICATION, AND/OR OVEREXPRESSION DEFINES DIFFUSELY INVASIVE TUMOR CELLS IN PEDIATRIC AND ADULT GLIOBLASTOMA. Neuro-Oncology, 2016, 18, vi46-vi46.	1.2	0
113	MBRS-62. REPRESSIVE CHROMATIN REMODELERS IN SHH-DRIVEN MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i141-i141.	1.2	0
114	PDTM-11. A NOVEL EX VIVO MODEL FOR HUMAN MEDULLOBLASTOMA: A NEW PERSONALIZED MEDICINE TOOL. Neuro-Oncology, 2018, 20, vi206-vi206.	1.2	0
115	RTHP-20. PEDIATRIC HIGH GRADE GLIOMAS: PATTERNS OF FAILURE AND OUTCOMES WITH LIMITED MARGIN RADIOTHERAPY. Neuro-Oncology, 2018, 20, vi229-vi229.	1.2	0
116	PDTM-45. POSITIVE MODULATION OF NATIVE GABAA RECEPTORS IN MEDULLOBLASTOMA CANCER CELLS WITH BENZODIAZEPINES INDUCES RAPID MITOCHONDRIAL FRAGMENTATION AND TP53-DEPENDENT, CELL CYCLE-INDEPENDENT APOPTOSIS. Neuro-Oncology, 2018, 20, vi213-vi213.	1.2	0
117	IMMU-25. RADIO-IMMUNOTHERAPY USING THE IDO PATHWAY INHIBITOR INDOXIMOD FOR CHILDREN WITH NEWLY-DIAGNOSED DIPG. Neuro-Oncology, 2018, 20, i103-i104.	1.2	0
118	PDTM-11. GAINING INSIGHTS INTO THE INFLAMMATORY MICROENVIRONMENT OF PEDIATRIC HIGH-GRADE GLIOMAS USING GEMMs AND PATIENT SAMPLES. Neuro-Oncology, 2019, 21, vi189-vi189.	1.2	0
119	PDTM-44. ROLE OF ONC-206 IN REGULATING MEDULLOBLASTOMA TUMOR PROGRESSION. Neuro-Oncology, 2019, 21, vi196-vi197.	1.2	0
120	HGG-37. UPFRONT TARGETED THERAPY FOR THE TREATMENT OF BRAFV600E-MUTANT PEDIATRIC HIGH-GRADE GLIOMA â€“ A MULTI-INSTITUTIONAL EXPERIENCE. Neuro-Oncology, 2021, 23, i25-i25.	1.2	0
121	ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG.. Journal of Clinical Oncology, 2020, 38, 3619-3619.	1.6	0
122	DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG. Neuro-Oncology, 2020, 22, iii297-iii297.	1.2	0
123	IMG-04. RESPONSE ASSESSMENT IN PEDIATRIC HIGH-GRADE GLIOMA: RECOMMENDATIONS FROM THE RESPONSE ASSESSMENT IN PEDIATRIC NEURO-ONCOLOGY WORKING GROUP. Neuro-Oncology, 2020, 22, iii355-iii355.	1.2	0
124	PATH-14. GENETIC SUSCEPTIBILITY AND OUTCOMES OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT IDH-MUTANT ASTROCYTOMAS. Neuro-Oncology, 2020, 22, iii427-iii427.	1.2	0
125	QOL-31. USE OF PATIENT-REPORTED OUTCOMES TO IDENTIFY YOUTH AT RISK FOR IMPAIRED OVERALL HEALTH. Neuro-Oncology, 2020, 22, iii437-iii437.	1.2	0
126	High-Grade Tumors of the Brainstem (Except DIPG). , 2020, , 145-158.		0

#	Article	IF	Citations
127	EXTH-62. PRECLINICAL EFFICACY OF THE IMIPRIDONE ONC-206 AGAINST MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, ii100-ii101.	1.2	0